pharmaphorum
MARCH 22, 2022
Virtual and augmented reality tools have reached a level of maturity to be utilised across various industries. In this article, Ben Hargreaves asks whether there is particular potential for the technologies to revolutionise staff training and reduce costs in pharma manufacturing. Virtual reality (VR) and augmented reality (AR) have spent a lot of time in the headlines recently.
Outsourcing Pharma
MARCH 22, 2022
The agency has approved Lynparza for use in the US as an adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MARCH 22, 2022
Voyager Therapeutics has lost little time in elevating Al Sandrock to the chief executive position, with the appointment coming just a few weeks after he joined the biotech’s board. Sandrock announced he was ending a 23-year career at Biogen last November, in the wake of the company’s controversial approval and disastrous rollout of Alzheimer’s therapy Aduhelm (aducanumab).
Pharma Mirror
MARCH 22, 2022
SmiLe Incubator’s angel investment company, SmiLe Inject Capital, invests 2 MSEK in Call Knut, an incubator company that is developing a voice robot- based service using AI and ordinary phone calls as a complement in communicating with and caring for elderly people living on their own. The investment will be used to complete the development of the product and enable a commercial launch during the year.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
MARCH 22, 2022
metaMe Health has enlisted the aid of health tech company Indegene to launch its recently-approved prescription digital therapeutic (DTx) Regulora for irritable bowel syndrome in the US. The digital health company got a green light from the FDA last November for Regulora – which delivers hypnotherapy through an Apple or Android smartphone – as a therapy for abdominal pain associated with all forms of IBS.
Pharma Mirror
MARCH 22, 2022
PRINCETON, N.J. and CHICAGO. Indegene, a technology-led global healthcare solutions provider, and metaMe Health, Inc. (metaMe), a Prescription Digital Therapeutics (PDT) company and developer of Regulora®, today announced a partnership to bring Regulora to market for the treatment of abdominal pain due to Irritable Bowel Syndrome (IBS). IBS is a chronic condition that affects 10-15% of adults in the United States.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Outsourcing Pharma
MARCH 22, 2022
The pharmaceutical company has agreed to provide its Paxlovid oral COVID-19 treatment to the global charity, covering 95 low- and middle-income countries.
pharmaphorum
MARCH 22, 2022
Tanya Brinsden, senior VP of operations at ICON Global Medical Communications and Pubs Hub, Jessica Cherian, VP of content and strategic services at ICON Market Access and Reimbursement, and Béranger Lueza, principal Health Economics (HE) at ICON Global Health Economics, Outcomes Research and Epidemiology (GHEORE), discuss how essential a data-driven strategy is to successfully communicate a brand’s value proposition in a competitive market.
Pharma Times
MARCH 22, 2022
Approval of Exkivity could mean NHS access to ground-breaking treatment for patients with rare lung cancer
pharmaphorum
MARCH 22, 2022
21GRAMS takes 6 Golds – Novartis tops the pharma leader board. The PM Society’s 36th annual awards was held on 11th March 2022 at the Grosvenor House Hotel in London. After two years apart, due to the pandemic, the industry was back together to celebrate the best creative communications in pharma and healthcare. An address by PM Society Co-Chairs Caroline Benson and Colin Williams kicked off the afternoon, with charity DEBRA taking the stage to ask for support.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharma Times
MARCH 22, 2022
Patients with a life-limiting skeletal condition welcome availability of elosulfase alfa on the NHS
pharmaphorum
MARCH 22, 2022
Bavarian Nordic has licensed rights to its respiratory syncytial virus (RSV) vaccine in China and certain other Asian markets to Shanghai’s Nuance Pharma in a $225 million deal. The agreement, which also covers South Korea, Taiwan and certain markets in Southeast Asia, will see Nuance take the lead on a phase 3 trial of the MVA-BN RSV vaccine in China that will run separately to Bavarian Nordics own pivotal trial.
pharmaphorum
MARCH 22, 2022
Merck & Co’s KEYNOTE-158 trial of Keytruda has underpinned another FDA approval, this time for the PD-1 inhibitor as a single-agent therapy as a therapy for endometrial cancer with certain genetic mutations. Keytruda (pembrolizumab) has been cleared for patients with advanced endometrial cancer whose tumours have microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) mutations, and have progressed after earlier systemic therapy, and who are not eligible for curativ
Expert insights. Personalized for you.
137 
Let's personalize your content